Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012060986> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2012060986 endingPage "77" @default.
- W2012060986 startingPage "77" @default.
- W2012060986 abstract "We studied the effect of entacapone, a selective catechol-O-methyltransferase inhibitor, on the bioavailability and clinical effect of levodopa in Parkinson9s disease (PD). On day 1 (control day), nine patients received their own levodopa (plus benserazide) medication only; for the next 7 days they received 200 mg of entacapone with each dose of levodopa (tid or qid). We evaluated disability in the morning (8 AM) before drug administration and then at 1-hour intervals until 6 PM on days 1, 2, and 8, using a modified motor part of the Unified Parkinson9s Disease Rating Scale. Repeated blood samples were taken before and during the 4 hours after the morning drugs for pharmacokinetic evaluation of entacapone and of levodopa and its metabolites. Added to the levodopa treatment, entacapone decreased clinical disability by about 16% (<i>p</i> < 0.05) from day 1 to day 8. The area under the curve (AUC) of levodopa increased by 38% (<i>p</i> < 0.01) after administration of a single dose of entacapone and by 40% (<i>p</i> < 0.05) after 7 days of multiple dosing with entacapone. Entacapone did not change the T<sub>max</sub> and C<sub>max</sub> values of levodopa. After 7 days of treatment with entacapone, the AUC of 3-O-methyldopa had decreased by 44% (<i>p</i> < 0.01) and of homovanillic acid by 26% (<i>p</i> < 0.05) as compared with treatment with levodopa alone. Four patients became slightly more dyskinetic during entacapone treatment than before it. The combination of entacapone and levodopa was well tolerated, judged by the lack of significant changes in hemodynamic and safety variables. We conclude that entacapone may be a helpful adjunct to levodopa in the treatment of PD." @default.
- W2012060986 created "2016-06-24" @default.
- W2012060986 creator A5017239100 @default.
- W2012060986 creator A5017864665 @default.
- W2012060986 creator A5029389310 @default.
- W2012060986 creator A5064866447 @default.
- W2012060986 creator A5080874752 @default.
- W2012060986 date "1994-01-01" @default.
- W2012060986 modified "2023-09-27" @default.
- W2012060986 title "Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients" @default.
- W2012060986 doi "https://doi.org/10.1212/wnl.44.1.77" @default.
- W2012060986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8290096" @default.
- W2012060986 hasPublicationYear "1994" @default.
- W2012060986 type Work @default.
- W2012060986 sameAs 2012060986 @default.
- W2012060986 citedByCount "106" @default.
- W2012060986 countsByYear W20120609862012 @default.
- W2012060986 countsByYear W20120609862013 @default.
- W2012060986 countsByYear W20120609862014 @default.
- W2012060986 countsByYear W20120609862015 @default.
- W2012060986 countsByYear W20120609862017 @default.
- W2012060986 countsByYear W20120609862018 @default.
- W2012060986 countsByYear W20120609862019 @default.
- W2012060986 countsByYear W20120609862022 @default.
- W2012060986 crossrefType "journal-article" @default.
- W2012060986 hasAuthorship W2012060986A5017239100 @default.
- W2012060986 hasAuthorship W2012060986A5017864665 @default.
- W2012060986 hasAuthorship W2012060986A5029389310 @default.
- W2012060986 hasAuthorship W2012060986A5064866447 @default.
- W2012060986 hasAuthorship W2012060986A5080874752 @default.
- W2012060986 hasConcept C104317684 @default.
- W2012060986 hasConcept C112705442 @default.
- W2012060986 hasConcept C126322002 @default.
- W2012060986 hasConcept C180754005 @default.
- W2012060986 hasConcept C185361966 @default.
- W2012060986 hasConcept C185592680 @default.
- W2012060986 hasConcept C2776976799 @default.
- W2012060986 hasConcept C2779026782 @default.
- W2012060986 hasConcept C2779134260 @default.
- W2012060986 hasConcept C2779734285 @default.
- W2012060986 hasConcept C2780304432 @default.
- W2012060986 hasConcept C55493867 @default.
- W2012060986 hasConcept C71924100 @default.
- W2012060986 hasConcept C76318530 @default.
- W2012060986 hasConcept C98274493 @default.
- W2012060986 hasConceptScore W2012060986C104317684 @default.
- W2012060986 hasConceptScore W2012060986C112705442 @default.
- W2012060986 hasConceptScore W2012060986C126322002 @default.
- W2012060986 hasConceptScore W2012060986C180754005 @default.
- W2012060986 hasConceptScore W2012060986C185361966 @default.
- W2012060986 hasConceptScore W2012060986C185592680 @default.
- W2012060986 hasConceptScore W2012060986C2776976799 @default.
- W2012060986 hasConceptScore W2012060986C2779026782 @default.
- W2012060986 hasConceptScore W2012060986C2779134260 @default.
- W2012060986 hasConceptScore W2012060986C2779734285 @default.
- W2012060986 hasConceptScore W2012060986C2780304432 @default.
- W2012060986 hasConceptScore W2012060986C55493867 @default.
- W2012060986 hasConceptScore W2012060986C71924100 @default.
- W2012060986 hasConceptScore W2012060986C76318530 @default.
- W2012060986 hasConceptScore W2012060986C98274493 @default.
- W2012060986 hasIssue "1" @default.
- W2012060986 hasLocation W20120609861 @default.
- W2012060986 hasLocation W20120609862 @default.
- W2012060986 hasOpenAccess W2012060986 @default.
- W2012060986 hasPrimaryLocation W20120609861 @default.
- W2012060986 hasRelatedWork W1965128384 @default.
- W2012060986 hasRelatedWork W1996321703 @default.
- W2012060986 hasRelatedWork W2018371145 @default.
- W2012060986 hasRelatedWork W2020613687 @default.
- W2012060986 hasRelatedWork W2060750200 @default.
- W2012060986 hasRelatedWork W2062647602 @default.
- W2012060986 hasRelatedWork W2077644178 @default.
- W2012060986 hasRelatedWork W2122137453 @default.
- W2012060986 hasRelatedWork W2126118728 @default.
- W2012060986 hasRelatedWork W2398012774 @default.
- W2012060986 hasVolume "44" @default.
- W2012060986 isParatext "false" @default.
- W2012060986 isRetracted "false" @default.
- W2012060986 magId "2012060986" @default.
- W2012060986 workType "article" @default.